Cardiovascular-Renal Consequences of Reducing Renal Mass After Living Kidney Donation

Hypertension Clinical Trial

Official title:

Cardiovascular-Renal Consequences of Reducing Renal Mass After Living Kidney Donation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01564966
• Other study ID #: 20120209
• Secondary ID: 4369
• Status: Completed
• Phase: N/A
• First received: March 25, 2012
• Last updated: March 28, 2012
• Start date: April 2008
• Est. completion date: December 2011

Study information

• Verified date: March 2012
• Source: Istanbul University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Turkey: Ministry of Health
• Study type: Observational

Clinical Trial Summary

• A reduce in renal mass may result in remnant single nephron hyperfiltration, with associated proteinuria and an accelerated loss of kidney function.

• Live-donor kidney transplantation is generally considered the best choice for patients who have renal failure and are awaiting transplantation, because these kidneys function better than kidneys from deceased donors, and waiting times for deceased-donor transplants are long

• Although several studies have shown that kidney donation has low short-term morbidity and mortality, the data on long-term outcomes are much less complete.

• This study is designed to prospectively evaluate the effects of unilateral nephrectomy on cardiovascular-renal functions of donors after living kidney donation: the development of hypertension, albuminuria, renal failure, inflammatory and endothelial changes.

Description:

Renal dysfunction is associated with accelerated cardiovascular disease even when kidney function is only mildly impaired. Besides, even levels of urinary albumin excretion below the accepted threshold for microalbuminuria are associated with increased cardiovascular risk, and the risk increases as the degree of proteinuria rises.

• Live-donor kidney transplantation is generally considered the best choice for patients who have renal failure and are awaiting transplantation, because these kidneys function better than kidneys from deceased donors, and waiting times for deceased-donor transplants are long. Although several studies have shown that kidney donation has low short-term morbidity and mortality, the data on long-term outcomes are much less complete. The short and long term renal functions of donors after kidney donation were much studied and still remain uncertain, the cardiovascular effects of reduction in renal mass in kidney donors is also not clearly known.

• Endothelial dysfunction (ED) is the first step for subsequent development of atherosclerosis, which can help us to assess the cardiovascular changes after kidney donation. Prospectively examining the endothelial consequences of uninephrectomy in donors may provide useful insight into the existence and pathophysiology of cardiovascular disease in donors and, therefore, into how the cardiovascular disease risk associated with renal impairment might eventually be reduced.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Est. completion date: December 2011
• Est. primary completion date: September 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• living kidney donors

• Ages of 18 and 70

• Creatinine clearance at donation > 80 ml/min/1.73 m2

Exclusion Criteria:

• Low (< 80 ml/min/1.73 m2) creatinine clearance at donation

• Diabetes mellitus

• Hypertension

• Valvular heart disease, any prior coronary intervention

• Congestive heart failure (New York Heart Association class II or greater)

• Cardiac arrhythmia

• A history of cerebral infarction or transient ischemic attack

• Active infection or non-infectious overt inflammation

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Albuminuria
• Endothelial Dysfunction
• Hypertension
• Inflammation
• Kidney Failure
• Renal Failure
• Renal Insufficiency

Locations

Country	Name	City	State
Turkey	Division of Nephrology, Istanbul Faculty of Medicine, Istanbul University	Istanbul

Sponsors (1)

Lead Sponsor	Collaborator
Istanbul University

Country where clinical trial is conducted

Turkey,